Literature DB >> 20738806

Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo.

Kyle A DiVito1, Valerie A Trabosh, You-Shin Chen, Yu Chen, Chris Albanese, Delphine Javelaud, Alain Mauviel, Cynthia M Simbulan-Rosenthal, Dean S Rosenthal.   

Abstract

The list of transforming growth factor-beta (TGF-β)-related proteins in non-canonical TGF-β signaling is growing. Examples include receptor-Smads directing micro-RNA processing and inhibitory-Smads, e.g. Smad7, directing cell adhesion. Human skin grafts with fluorescently tagged melanoma cells revealed Smad7-expressing cells positioned themselves proximal to the dermal-epidermal junction and failed to form tumors, while control cells readily invaded and formed tumors within the dermis. Smad7 significantly inhibited β-catenin T41/S45 phosphorylation associated with degradation and induced a 4.5-fold increase in full-length N-cadherin. Cell adhesion assays confirmed a strong interaction between Smad7-expressing cells and primary dermal fibroblasts mediated via N-cadherin, while control cells were incapable of such interaction. Immunofluorescent analysis of skin grafts indicated N-cadherin homotypic interaction at the surface of both Smad7 cells and primary dermal fibroblasts, in contrast to control melanoma cells. We propose that Smad7 suppresses β-catenin degradation and promotes interaction with N-cadherin, stabilizing association with neighboring dermal fibroblasts, thus mitigating invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738806      PMCID: PMC2975252          DOI: 10.1111/j.1755-148X.2010.00758.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  45 in total

1.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

Authors:  Thorsten Maretzky; Karina Reiss; Andreas Ludwig; Julian Buchholz; Felix Scholz; Erhardt Proksch; Bart de Strooper; Dieter Hartmann; Paul Saftig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

Review 2.  Smad transcription factors.

Authors:  Joan Massagué; Joan Seoane; David Wotton
Journal:  Genes Dev       Date:  2005-12-01       Impact factor: 11.361

3.  Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands.

Authors:  Hiroo Ueno; Irving L Weissman
Journal:  Dev Cell       Date:  2006-10       Impact factor: 12.270

Review 4.  Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

Authors:  Karl-Hermann Schlingensiepen; Reimar Schlingensiepen; Andreas Steinbrecher; Peter Hau; Ulrich Bogdahn; Birgit Fischer-Blass; Piotr Jachimczak
Journal:  Cytokine Growth Factor Rev       Date:  2005-12-27       Impact factor: 7.638

5.  Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition.

Authors:  Masato Maeda; Keith R Johnson; Margaret J Wheelock
Journal:  J Cell Sci       Date:  2005-02-15       Impact factor: 5.285

6.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 7.  ADAMs in cancer cell proliferation and progression.

Authors:  Satsuki Mochizuki; Yasunori Okada
Journal:  Cancer Sci       Date:  2007-03-09       Impact factor: 6.716

8.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis.

Authors:  Delphine Javelaud; Khalid S Mohammad; Christopher R McKenna; Pierrick Fournier; Flavie Luciani; Maryla Niewolna; Jocelyne André; Véronique Delmas; Lionel Larue; Theresa A Guise; Alain Mauviel
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

9.  Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein.

Authors:  Christian J Schmitt; Werner W Franke; Sergij Goerdt; Berit Falkowska-Hansen; Steffen Rickelt; Wiebke K Peitsch
Journal:  J Invest Dermatol       Date:  2007-05-10       Impact factor: 8.551

10.  Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma.

Authors:  Gretchen M Kreizenbeck; Aaron J Berger; Antonio Subtil; David L Rimm; Bonnie E Gould Rothberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

View more
  12 in total

1.  TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.

Authors:  Khalid S Mohammad; Delphine Javelaud; Pierrick G J Fournier; Maria Niewolna; C Ryan McKenna; Xiang H Peng; Vu Duong; Lauren K Dunn; Alain Mauviel; Theresa A Guise
Journal:  Cancer Res       Date:  2010-11-16       Impact factor: 12.701

2.  Expression of microphthalmia-associated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GLI2 and transforming growth factor-β.

Authors:  Marie-Jeanne Pierrat; Véronique Marsaud; Alain Mauviel; Delphine Javelaud
Journal:  J Biol Chem       Date:  2012-04-11       Impact factor: 5.157

3.  N-cadherin participated in invasion and metastasis of human esophageal squamous cell carcinoma via taking part in the formation of vasculogenic mimicry.

Authors:  Feng Wang; Xiang-Ke Li; Hong-Yan Xu; Zheng-Zheng Shan; Tao Wang; Zi-Chang Yang; Wei He; Liu-Xing Wang; Qing-Xia Fan
Journal:  Med Oncol       Date:  2015-01-10       Impact factor: 3.064

4.  Id2, Id3 and Id4 overcome a Smad7-mediated block in tumorigenesis, generating TGF-β-independent melanoma.

Authors:  Kyle A DiVito; Cynthia M Simbulan-Rosenthal; You-Shin Chen; Valerie A Trabosh; Dean S Rosenthal
Journal:  Carcinogenesis       Date:  2013-12-16       Impact factor: 4.944

Review 5.  Wnt/beta-catenin signaling and small molecule inhibitors.

Authors:  Andrey Voronkov; Stefan Krauss
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 6.  The dual role of Smad7 in the control of cancer growth and metastasis.

Authors:  Carmine Stolfi; Irene Marafini; Veronica De Simone; Francesco Pallone; Giovanni Monteleone
Journal:  Int J Mol Sci       Date:  2013-12-05       Impact factor: 5.923

7.  Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.

Authors:  Edna Gordian; Jiannong Li; Yuri Pevzner; Melanie Mediavilla-Varela; Kimberly Luddy; Kim Ohaegbulam; Kenyon G Daniel; Eric B Haura; Teresita Muñoz-Antonia
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

Review 8.  The role of Smad7 in oral mucositis.

Authors:  Li Bian; Gangwen Han; Carolyn W Zhao; Pamela J Garl; Xiao-Jing Wang
Journal:  Protein Cell       Date:  2015-01-08       Impact factor: 14.870

9.  Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.

Authors:  Carole Yolande Perrot; Delphine Javelaud; Alain Mauviel
Journal:  Ann Dermatol       Date:  2013-05       Impact factor: 1.444

10.  SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer.

Authors:  Huidi Liu; Emilio Mastriani; Zi-Qiao Yan; Si-Yuan Yin; Zheng Zeng; Hong Wang; Qing-Hai Li; Hong-Yu Liu; Xiaoyu Wang; Hong-Xia Bao; Yu-Jie Zhou; Jun-Jie Kou; Dongsheng Li; Ting Li; Jianrui Liu; Yongfang Liu; Lin Yin; Li Qiu; Liling Gong; Shu-Lin Liu
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.